Haleon plc (LON:HLN - Get Free Report) shares traded down 0.6% during mid-day trading on Tuesday . The stock traded as low as GBX 384.60 ($5.17) and last traded at GBX 388.60 ($5.23). 17,750,443 shares traded hands during trading, a decline of 32% from the average session volume of 26,079,627 shares. The stock had previously closed at GBX 391 ($5.26).
Wall Street Analysts Forecast Growth
Separately, Berenberg Bank increased their target price on Haleon from GBX 456 ($6.13) to GBX 457 ($6.15) and gave the stock a "buy" rating in a research note on Friday, February 28th.
View Our Latest Stock Analysis on Haleon
Haleon Stock Up 0.5%
The company has a debt-to-equity ratio of 53.36, a quick ratio of 0.93 and a current ratio of 0.84. The company has a market cap of £34.70 billion, a price-to-earnings ratio of 32.34, a price-to-earnings-growth ratio of 1.49 and a beta of 0.19. The business has a 50-day simple moving average of GBX 396.07 and a 200-day simple moving average of GBX 387.06.
Insider Buying and Selling at Haleon
In related news, insider Marie-Anne Aymerich purchased 21,300 shares of Haleon stock in a transaction on Friday, May 9th. The shares were bought at an average price of GBX 405 ($5.45) per share, with a total value of £86,265 ($116,009.95). Also, insider Blathnaid Bergin purchased 6,145 shares of Haleon stock in a transaction on Friday, May 16th. The stock was bought at an average cost of GBX 404 ($5.43) per share, for a total transaction of £24,825.80 ($33,385.96). Insiders have purchased 42,869 shares of company stock valued at $17,294,104 in the last quarter. Corporate insiders own 10.74% of the company's stock.
About Haleon
(
Get Free Report)
Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.
Featured Stories
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.